Ondrus D, Schnorrer M, Cársky S, Belan V, Kausitz J, Matoska J
Urologická klinika, NsP akad. L. Dérera v Bratislave.
Bratisl Lek Listy. 1992 Jan;93(1):27-31.
The efficacy of combined cytostatic-surgical treatment was evaluated in a prospective study involving 70 patients with germinal tumors of the testis metastasizing into the lungs. Complete remission was achieved in 50 (71.4%) patients, 30 of these received only chemotherapy. Thoracotomy was performed in 14 patients with residual pulmonary CT finding, 6 of them underwent bilateral operations. Of the total 21 operations of the lungs residual malignant tumor was found 4 times. After a mean follow up period of 29.8 months since onset of treatment 48 patients (68.6%) survived. Within a mean of 11.4 months after onset of treatment 22 patients (31.4%) died. The authors consider thoracotomy with resection of the metastatic focus to be the only method for determining reliably the biological nature of the residual pulmonary lesion after chemotherapy. The result of the procedure determines the further measures, i.e. sequential chemotherapy or regular check ups. (Tab. 1, Fig. 6, Ref. 15.).
在一项涉及70例睾丸生殖细胞瘤肺转移患者的前瞻性研究中，评估了细胞抑制-手术联合治疗的疗效。50例（71.4%）患者实现完全缓解，其中30例仅接受了化疗。14例肺部CT有残留表现的患者接受了开胸手术，其中6例接受了双侧手术。在总共21例肺部手术中，有4次发现残留恶性肿瘤。自治疗开始后的平均随访期为29.8个月，48例（68.6%）患者存活。治疗开始后的平均11.4个月内，22例（31.4%）患者死亡。作者认为，开胸切除转移灶是可靠确定化疗后肺部残留病变生物学性质的唯一方法。该手术结果决定进一步的措施，即序贯化疗或定期检查。（表1，图6，参考文献15。）
